BioCentury Inc.

Base editor efficiency boom. China leading charge? Recently published studies reveal advances in precision and performance, with most innovations coming out of China

BioCentury Inc.'s #GrandRoundsUS Conference is coming to Chicago, June 4-6, 2025—bringing together global biotech leaders, investors, and innovators. Mark your calendars and get ready for groundbreaking discussions shaping the future of healthcare.     🚨 Investors: Bring your next-generation partners and colleagues to one or both Grand Rounds meetings with our special VC rate when you register by April 15, with extra savings for bundles of four passes or more. Email conferences@biocentury.com to receive the code.    #GrandRoundsUS #ChicagoBiotech  📅 Date: June 4-6, 2025  📍 Location: Chicago, IL 

🚨 #Investors: You know that in the current economic landscape, identifying the right investment opportunities can be complex. #BioCenturyGrandRounds streamlines this process by connecting VCs directly with top innovators and cutting-edge science. Join us in Chicago (right after #ASCO2025) and Cambridge, U.K. at a summit that delivers the right people in the room to network, partner and debate the details that matter. 💸 This is your last chance to save! Bring your next-generation partners and colleagues to one or both Grand Rounds meetings with our special #VC rate when you register by COB on April 11, with extra savings for bundles of four passes or more. Email conferences@biocentury.com to receive the code. Learn more and register at https://lnkd.in/gmhZ75vm.

As more NIH cuts loom, researchers warn U.S. science at risk. In addition to obvious blows, unseen damage could be lasting, NIH staff caution

🚨 Attention Biotech 🚨 BioCentury Inc. is conducting a brief survey to gauge industry sentiment about recent U.S. political developments. It's only 10 questions and open for a limited time. Submit your responses before the survey closes 👇 As a token of our appreciation, you’ll have the option to receive a copy of the survey results once it concludes. https://lnkd.in/e_xKA6JC

Hey Biotech folks, BioCentury Inc. is running a quick Sentiment survey to take the pulse of everyone in this climate. It's only open for a couple of days, please participate now - takes less than 5 minutes, beats doomscrolling: https://lnkd.in/eHjm3rzu

🎙️ This week on the #BioCenturyThisWeek podcast, BioCentury editors analyze key challenges facing biotech and investors: ➣ FDA Turmoil: How leadership changes, staffing cuts and reorganization are increasing risks for biotech ➣ Trade War Fallout: The impact of new tariffs on the sector and investment strategies ➣ #AACR25 Preview: Insights into VEGF-targeted bispecifics ahead of the annual cancer research meeting ➣ Market Outlook: Strategies for navigating a bear market, with insights from BioCentury's 2Q25 Financial Markets Preview (https://lnkd.in/gMU7MeT5) 🎧 Tune in on Spotify, Apple Podcasts, YouTube or your favorite podcast platform: https://lnkd.in/gJVDyjBA Thank you to the sponsor of this episode, RemeGen荣昌生物 / RemeGen Biosciences.

🤒It is time to take your temperature! ➢ How is your sentiment? ➢ How does your sentiment compare to #biopharma peers? 📝 Take the BioCentury sentiment survey: https://lnkd.in/dxEH98BG It's anonymous. Takes one minute. It's more productive than doom scrolling! Don't wait, survey closes soon. #biotech #pharma #venturecapital #FDA #NIH #tariffs #XBI

Missed our live discussion? Now’s your chance to catch up! 👇 In this on-demand webinar presented by BioCentury Inc. and Oppenheimer & Co. Inc., we explore how policy shifts, economic trends and investor sentiment are shaping the future of biotech. With the sector facing strong headwinds after one of its toughest downturns, this session dives into the key drivers that could help biotechs rise above the noise. 📺 Watch it on-demand now: https://lnkd.in/gx5HZGSA #Biotech #CapitalMarkets #WebinarOnDemand #BioCentury #Oppenheimer #biopharma #venturecapital #IPO

We are excited to welcome FundPlus, J.P. Morgan, MTS Health Partners and Panacea Venture as official sponsors of the 25th Bio€quity Europe!   FundPlus is an open-ended Fund for long term equity investment in innovative Life Sciences companies with a focus on Belgium. They want to create sustainable shareholders value, contribute to the development of a leadership position in the Life Sciences sector and generate a tangible, beneficial societal impact.   J.P. Morgan is a global leader in financial services, providing comprehensive, scalable solutions in investment banking, commercial banking, financial transaction processing and asset management. Committed to being the leading bank for the innovation economy, J.P. Morgan and its bankers across the globe, provide venture-backed and high-growth companies with specialized services, access to a robust professional and venture capital network and money-management solutions.   MTS Health Partners is a leading boutique investment bank that provides strategic and financial advice to the healthcare industry. For 25 years, MTS has offered their clients unmatched strategic and M&A advisory services and equity and structured financing expertise. They foster trusted client partnerships, creating alignment to achieve their goals. They provide their clients with creative thinking, candid advice, and commitment to results, advising them in pursuing the right strategic pathways rather than simply focusing on transactions.   Panacea Venture is a life sciences venture firm with global vision and reach dedicated to transforming lives through promising innovation. Spun out from Kleiner Perkins, the founding partners sought to build a global firm, investing in innovation in every geography, while bringing their unique perspectives in life sciences to benefit global company building. Panacea leverages its venture operator model and invests across emerging and established companies in the therapeutics, diagnostics, medtech and CRO sectors.     On behalf of BioCentury Inc., EBD Group and Insights Partner McKinsey & Company, we are looking forward to having you at our CEO & investor Summit in Bruges, May 12-14, 2025.   Join biopharma leaders and VCs in Belgium as we dive into East-West dealmaking and debate what is next for the European biotech ecosystem. Register at www.bioequityeurope.com.   Download the conference brochure to review the agenda, presenting companies and who you will meet: https://lnkd.in/gFch8JnC View all sponsors: https://lnkd.in/gv9_vmFh